BPC-157
BPC · 5 mg · daily, dosed in mcg
SCIENCE • STRENGTH • LONGEVITY
Before you draw anything. Every figure in this document assumes a 5 mg vial reconstituted with 2.0 mL of bacteriostatic water. Change either number and every unit measurement here changes with it. Confirm the milligram strength printed on your vial first.
Micrograms, not milligrams. BPC-157 is dosed in micrograms while most of the catalog is dosed in milligrams. A 250 mcg dose is a quarter of one milligram. Mixing the two units up is the single most common error on this compound and produces a 1,000-fold mistake. Label the vial in mcg.
BPC-157 is a 15-amino-acid peptide originally isolated from gastric juice. Animal research links it to blood vessel formation at injury sites and to tissue protection, with the largest body of preclinical work covering tendon, ligament, and gut tissue.
RECONSTITUTION
| Parameter | Value |
|---|---|
| Vial | 5 mg (5,000 mcg) |
| Bacteriostatic water | 2.0 mL |
| Concentration | 2,500 mcg/mL |
| Conversion | 10 units = 250 mcg · 20 units = 500 mcg · 1 unit = 25 mcg |
| Route | Subcutaneous, near the area of interest |
| Reconstituted storage | 2–8 °C, up to 30 days |
| Lyophilized storage | −20 °C, 12+ months |
- Let the vial and the bacteriostatic water reach room temperature.
- Swab both stoppers with alcohol and let them dry.
- Draw the planned volume of bacteriostatic water into a sterile syringe.
- Aim the stream at the inside wall of the glass, never directly at the powder.
- Roll gently for 30 to 60 seconds until fully dissolved. Never shake — shaking damages the peptide.
- Confirm the solution is clear before use.
- Label with product, concentration, and date, then refrigerate.
DOSING SCHEDULE
| Phase | Amount | Units | Frequency | Duration |
|---|---|---|---|---|
| Loading | 250–500 mcg | 10–20 | Daily | Weeks 1–4 |
| Maintenance | 250 mcg | 10 | Daily | Weeks 5–8 and beyond |
Vial coverage
| Amount per day | Units | Days per 5 mg vial |
|---|---|---|
| 250 mcg | 10 | 20 days |
| 500 mcg | 20 | 10 days |
At the 500 mcg loading amount a single vial runs out inside two weeks, well before the 30-day stability window closes. A four-week loading phase needs two vials.
Notes
- Inject subcutaneously near the area of interest where practical. Unlike TB-500, proximity is part of the common protocol.
- Daily dosing without a scheduled off-day during the loading phase.
- Reported effects are mild and infrequent — injection-site irritation is the most common.
- Rotate within the general area rather than using one exact spot.
- Never combine with another compound in the same syringe.
Relationship to GLOW 70
GLOW 70 contains BPC-157 at roughly 0.33 mg — 330 mcg — per daily draw, which sits inside the standard standalone range. Unlike the TB-500 fraction of that blend, the BPC-157 content is not underdosed. Running standalone BPC-157 alongside GLOW is genuinely redundant rather than complementary.
CAUTIONS
- Active cancer or a strong cancer history. BPC-157 promotes angiogenesis, which is the mechanism a tumor depends on to expand.
- Active retinal vascular disease or other conditions sensitive to angiogenic signaling.
- Pregnancy or breastfeeding — no safety data exists.
- Prohibited by WADA at all times, in and out of competition.
- Removed from the FDA bulk-substance list for compounding, which is a change in regulatory posture worth being aware of.
Supplies
- U-100 insulin syringes, 0.3 mL / 30-unit. Half-unit gradations matter at these draw volumes.
- Bacteriostatic water, 10 mL bottle.
- Alcohol prep pads and a sharps container.
Record keeping
Log the date, units drawn, and site for every injection, alongside any symptoms. This catches gradual dose drift, and if something does go wrong it identifies exactly which step it started on.